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Background: We studied recent trends in mortality from seven mental and neurological conditions and their
determinants in 41 European countries.
Methods: Age-standardized mortality rates were analysed using standard methods of descriptive epidemiology,
and were related to cultural, economic and health care indicators using regression analysis.
Results: Rising mortality from mental and neurological conditions is seen in most European countries, and is
mainly due to rising mortality from dementias. Mortality from psychoactive substance use and Parkinson’s disease
has also risen in several countries. Mortality from dementias has risen particularly strongly in Finland, Iceland, Malta,
Netherlands, Spain, Sweden and the United Kingdom, and is positively associated with self-expression values, average
income, health care expenditure and life expectancy, but only the first has an independent effect.
Conclusions: Although trends in mortality from dementias have probably been affected by changes in cause-of-death
classification, the high level of mortality from these conditions in a number of vanguard countries suggests that it is
now among the most frequent causes of death in high-income countries. Recognition of dementias as a cause of
death, and/or refraining from life-saving treatment for patients with dementia, appear to be strongly dependent on
cultural values.
Keywords: Mortality, Mental and behavioural disorders, Diseases of the nervous system, Dementias, Psychoactive
substance use, Meningitis, Parkinson’s disease, Alzheimer’s disease, Multiple sclerosis, Epilepsy, World Value Survey, EuropeBackground
Over the past decades, mortality has declined substantially
in many European countries, as a result of declines for
many specific causes of death, particularly cardiovascular
disease. This has been interpreted by some as a new stage
in the epidemiologic transition, in which the mean age of
death shifts upwards [1], and the cause-of-death pattern
shifts towards diseases of very old age such as dementias
[2,3]. Some early authors have even warned for a
“pandemic of mental disorders and disabilities” [4,5].
It is indeed true that a slight shift in cause-of-death
patterns has been occurring in many European countries.
Mental and neurological diseases are among the very* Correspondence: j.mackenbach@erasmusmc.nl
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article, unless otherwise stated.small number of causes of death for which trends in
mortality moved in a different direction as compared to
all-cause mortality. While the correlation between trends
in all-cause mortality and cause-specific mortality is
usually positive, it is negative for mental and neurological
diseases (Figure 1; see Additional file 1 for background
material to these analyses).
As a result, the average proportion of all-cause mortality
that is due to mental and neurological diseases has gone
up sharply since the early 1970s (Figure 2). This should
not be exaggerated, as the average share of these
conditions in all-cause mortality is still below 5%, but it
already exceeds 10% among women in several countries.
Nevertheless, dementias have recently been reported to be
among the top-10 (men) or even top-5 (women) of most
frequent causes of death in several high-income countries
in Europe and elsewhere [6,7].entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
a. Men
b. Women
Figure 1 (See legend on next page.)
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Figure 1 Correlation between trends in all-cause mortality and trends in cause-specific mortality, European countries, 1970-2009.
a. Men. b. Women. Notes: We regressed age-adjusted cause-specific mortality rates and all-cause mortality rates, using ordinary least squares
regression, according to a method originally developed by Preston [Preston SH: Mortality patterns in national populations, with special reference
to recorded causes of death. New York: Academic Press; 1976.] but modified by us by including country dummies to allow for between-country
differences in levels of mortality. The graphs present partial correlation coefficients between cause-specific mortality rates on all-cause mortality
rates, controlling for country. Full regression results are given in web Additional file 1: Table S1.
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Previous studies have found that mortality from some
mental and neurological diseases has risen, while
mortality from other causes in this group has
remained stable or has even declined. Over the past
decades, many high-income countries have witnessed
a rise of age-adjusted mortality from dementia [8–11]
and motor neuron diseases [12–14], but reports on
trends in mortality from psychoactive substance use
[15–18], Parkinson’s disease [14,19,20], multiple sclerosis
[14,21,22] and epilepsy [14,23,24] have been less consistent.
Mortality from infectious diseases of the central nervous
system, such as meningitis, has declined [10].
Even when the direction of the trends is clear, their
interpretation is often uncertain, because they are not only
determined by trends in incidence and/or survival of these
conditions, but also by changes in recognition, diagnosis,
certification and coding of causes of death [9,11,14,25,26].
Over time, the International Classification of Diseases (ICD)
has undergone major changes in the chapters of “Mental
and behavioural disorders” and “Diseases of the nervous
system”. In addition, changes in coding rules have occurred
while a single ICD-revision was in use [9,11,25,26].Figure 2 The rising share of mental and neurological diseases in all-cau
Notes: Average of shares in each European country as calculated on the basis
related to the introduction of ICD-9, and irregularities in the early 1980s may b
for some years, and not for others.Nevertheless, it is possible that some of these
changes are real, and that some of these conditions
actually are more important as causes of death than
they were several decades ago. Potential explanations
for a real rise of dementia, for example, both as a
prevalent condition in the population and as a cause
of death, include better survival of people at risk of
developing dementia (e.g. better survival of people
with risk factors for vascular dementia due to more
effective prevention and treatment of ischemic heart
disease [27]). Explanatory studies are, however, rare.
We have therefore conducted an in-depth study of
trends in mortality from specific mental and neurological
conditions in Europe over the past 30 years. The main
study questions were:
– Which specific conditions account for the
rise of mortality from mental and neurological
diseases?
– What were the main variations in these trends
between European countries, and what clues do
these variations provide for the explanation of the
rise of mortality from these conditions?se mortality, European countries with available data, 1970–2006.
of age-standardized mortality rates. Irregularities around 1979 may be
e related to the fact that countries in the Soviet Union submitted data
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Data
Mortality data by year (1979–2009), country (n = 41),
sex, age (in 5-year age-groups, with 85+ as the highest
age-group) and cause of death were extracted from the
World Health Organization (WHO) Mortality Data Base
(updated November 2012). This dataset contains data on
underlying causes of death as officially registered by
member states, and as reported to WHO. We restricted
the analysis to the post-1979 period because this limited
the number of different editions of the International
Classification of Diseases (ICD) in use. Due to delays in
processing cause-of-death data, the most recent data
available for most countries relate to 2009. ICD-codes
for the causes of death analysed in this paper are given
in web Additional file 2: Table S2, which also includes
notes on issues related to cause-of-death classification in
this paper.
In addition to the broad chapters of “Mental and
behavioural disorders” and “Diseases of the nervous
system” we were able to look at seven specific (groups of)
causes of death: “dementias” (mainly vascular and
unspecified dementias), “mental disorders due to
psychoactive substance use” (mainly alcoholic psychosis
and alcohol and drug dependence), “meningitis” (some
forms of bacterial meningitis not elsewhere classified,
i.e. excluding meningococcal meningitis), “Parkinson’s
disease”, “Alzheimer’s disease c.a.” (mainly Alzheimer’s
disease, but including some other degenerative conditions
as well), “multiple sclerosis” and “epilepsy”.
Analysis
Mortality data were standardized for age (in five-year
age-groups until 85+) using the direct method and the
European standard population. In a first set of analyses
covering all specific conditions we studied all-age
mortality, but in subsequent more detailed analyses
for dementia we limited the analysis to those aged 65 and
over (which also practically eliminates any potential bias
due to the inclusion of other hereditary and degenerative
diseases of the nervous system).
Only some countries report mortality above the age of
85 with a further distinction by age, and because of the
steep gradient of some of these conditions (e.g. dementia)
against age we made some additional calculations based
on a finer distinction (85–90, 90–94, 95+) for those
countries for which this was possible.
We also explored some hypotheses relating to
factors that might influence mortality from mental and
neurological conditions. We conducted a regression
analysis with a forward selection procedure in which we
related mortality from mental and neurological conditions
to four variables, each representing a different class of
background factors:1. Self-expression values, as an indicator of cultural
conditions. We wondered whether health care
professionals in populations that adhere more
closely to values of self-expression and quality of life
instead of mere survival, might be more willing to
recognize mental and neurological conditions as a
possible cause of death, and/or to refrain from
life-saving treatments in dementia patients with
low quality of life. People in more advanced
industrialized countries have been shown to shift
their priorities from basic economic and physical
security towards subjective well-being, self-expression
and quality of life [28], and these self-expression vs.
survival values have been shown to be important
determinants of health, health behaviour and health
policy in Europe [29,30]. Data on self-expression vs.
survival values (countries’ mean standardized score as
measured between 2000 and 2006) were taken from
the World Values Survey [28].
2. Average income, as an indicator of economic
conditions. Research into the explanation of
between-country differences in health indicators
often finds that aggregate health outcomes are
closely correlated with national income, typically
measured by Gross Domestic Product (GDP) [31].
Recent studies have shown that, after a period with
diminished influence, average income has again
become an important determinant of national
mortality levels in Europe [32,33]. We wondered
whether richer countries would, on average, have
higher rates of mortality from mental and neurological
conditions, for example because they are more
advanced in their trajectories of epidemiological
transition [34,35]. Data on national income
(in 2008, as measured in 1990 I$1000s) per head
of population were extracted from a harmonized
dataset compiled by Maddison (http://www.ggdc.net/
MADDISON/oriindex.htm) [36].
3. Health care expenditure, as an indicator of health
care utilization. Due to its increasing effectiveness in
preventing and treating potentially fatal diseases,
health care has become a major determinant of
mortality in high income countries [37,38]. We
wondered whether countries with a larger health
care sector would, on average, have higher mortality
from mental and neurological conditions because
they have eliminated a larger proportion of
potentially amenable mortality [4,5]. We extracted
data on health care expenditure in 2008, as a
percentage of Gross Domestic Product, from the
World Health Organization Health for All Database
(http://data.euro.who.int/hfadb/).
4. Life expectancy at birth. Mortality from many
mental and neurological conditions occurs
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individuals who have escaped death from conditions
that kill at younger ages but who because of
remaining risk factors or high levels of frailty may be
at increased risk of dying from conditions of old age.
We therefore wondered whether countries with
higher life expectancy at birth would, on average,
have higher mortality from mental and neurological
conditions [4,5]. Data on life expectancy at birth in
2008, by gender, were extracted from the Human
Lifetable Database (www.lifetable.de), supplemented
by the World Health Organization Health for All
Database (http://data.euro.who.int/hfadb/).
Results
Table 1 presents some descriptive results for trends in
mortality from mental and neurological conditions in
Europe. Descriptive results for levels of mortality from these
conditions can be found in web Additional file 3: Table S3.
For both men and women, the median values (Q2) for
changes in mortality from all mental and neurological
conditions are positive in all three sub-periods (1981–1991,
1991–2000, 2000–2009) distinguished in this table,
implying increases in mortality for a large majority of
countries. Variation in mortality change for all mental
and neurological conditions between countries is, however,
substantial, as indicated by the interquartile range. The
values for the first quartile (Q1) are often negative,
implying declining mortality in at least a quarter of
all countries for which data were available. The values
for the third quartile (Q3) are much more strongly
positive than the median values, implying very rapid
rises in mortality in another group of countries.
For specific causes of death we also see large variations
between countries in mortality trends. For many causes of
death increases in some countries go together with declines
in others. Median values are consistently positive for
dementias, Parkinson’s disease, and Alzheimer’s c.a., imply-
ing rising mortality in a majority of countries. Meningitis is
the only condition for which median values are consistently
negative. For the remaining conditions, median values are
sometimes positive, sometimes negative, depending on the
time-period. When we focus on the third quartile values, to
identify the causes of rapidly rising mortality from all
mental and neurological diseases, we find that this must
primarily be due to rising mortality from dementias and
Alzheimer’s c.a., with some additional but much smaller
contribution from Parkinson’s disease (Table 1).
Figure 3 illustrates some of the rising mortality trends.
In order to allow for possible transfers between causes
of death, we combined dementias and Alzheimer’s c.a. in a
new group of “all dementias” (Figure 4a). Mortality from
this group has increased strongly in some Northern and
Western European countries, but also in Malta and Spain.In some countries (e.g. Netherlands, Spain) the trend
of mortality from all dementias has recently levelled
off, while in others (e.g. Finland, Malta) it continues to
rise. Mortality due to psychoactive substance use shows a
more erratic pattern, with very strong increases in Austria,
and a strong increase followed by a steep decline in
Finland (Figure 4b). Mortality from Parkinson’s disease
has risen strongly in Iceland and Finland again, but also in
Malta and Croatia (Figure 4c).
Because of the overwhelming importance of dementias
for the rise of mental and neurological diseases the remain-
der of our analysis focuses on this group of conditions.
Figure 4 shows the immense variation in mortality from all
dementias between European countries in 2009. The
variation is more than 50-fold between the country with
the highest mortality rate, Finland, and that with the lowest,
Bulgaria. There appears to be a North-west versus
South-east gradient, with higher mortality rates in, e.g.,
most of the Nordic countries and the Netherlands, and
lower mortality rates in the Baltic countries and in the
Balkans.
For many countries in the upper quarter of the European
distribution mortality data are available in a finer breakdown
by age, permitting a view on age-specific mortality rates
above the age of 85 (Figure 5). In these countries, mortality
from all dementias for those above the age of 95 is between
1 and 7% per year among men, and between 3 and 10% per
year among women. In these countries, mortality from
dementias now accounts for between 5% and 11% of all
deaths, and between 9% and 22% of all deaths above the age
of 85 (results not shown), and it generally ranks in the top-6
(men) and top-3 (women) of causes of death.
Table 2 shows the results of an exploratory regression
analysis. Mortality from all dementias is strongly associated
with each of the four variables included in the analysis: self-
expression values, average income, health care expenditure
and life expectancy at birth, both among men and women.
The strongest association is found for self-expression
values: the more a national population is oriented towards
modern self-expression values, the higher is mortality from
all dementias. After controlling for these values, none of
the other determinants is statistically significantly
associated with mortality from all dementias, while the
association with self-expression values mostly remains
statistically significant. A backward selection procedure, in
which variables are removed one-by-one from a full model
(results not shown), leads to the same conclusion:
self-expression values are the variable with the strongest
association with dementia mortality.
Discussion
Summary of findings
Rising mortality from mental and neurological conditions
is seen in most European countries, and is mainly due to
Table 1 Change in age-standardized mortality rates for mental and neurological disorders in Europe, 1981 – 2009:
median and first and third quartile values, by sex
Men Women
1981-91 1991-00 2000-09 1991-2009 1981-91 1991-00 2000-09 1991-2009
All mental and neurological # 18 26 32 26 17 25 32 26
Q1 -0.69 -0.60 -1.21 -1.39 -0.42 -0.18 0.67 0.92
Median (Q2) 5.28 2.86 2.61 2.78 1.74 2.48 3.47 7.61
Q3 9.75 9.20 6.71 8.44 7.69 8.66 7.37 13.15
Mental and behavioural disorders # 27 33 34 33 25 33 34 33
Q1 -1.64 -1.70 -2.71 -1.69 25 33 34 33
Median (Q2) 0.92 0.85 -1.11 0.93 0.37 0.40 0.08 0.86
Q3 3.93 4.00 1.52 5.00 1.31 3.01 1.65 5.79
Dementias # 17 23 23 20 17 23 26 23
Q1 0.05 -0.29 -0.54 -0.06 -0.70 -0.25 -0.67 -0.17
Median (Q2) 0.43 0.26 0.01 2.60 0.69 0.53 0.19 2.40
Q3 2.36 2.84 2.85 7.10 3.29 3.16 3.26 7.36
Psychoactive substance use # 17 24 30 24 17 22 25 21
Q1 -1.16 -1.39 -3.07 -3.67 0.11 -0.46 -0.54 -1.36
Median (Q2) 0.74 -0.22 -0.89 -1.10 0.54 -0.14 -0.09 -0.38
Q3 2.87 0.97 -0.01 0.13 0.70 0.20 0.30 0.08
Diseases of the nervous system # 17 24 31 25 17 24 31 25
Q1 -0.78 0.30 0.69 1.84 -0.48 0.10 0.30 1.41
Median (Q2) 1.58 2.14 3.08 3.67 0.60 1.89 3.31 3.38
Q3 3.37 3.28 4.61 7.50 3.02 3.63 4.86 6.38
Meningitis # 27 32 33 33 27 32 30 30
Q1 -0.55 -0.28 -0.49 -0.70 -0.50 -0.21 -0.17 -0.33
Median (Q2) -0.32 -0.05 -0.28 -0.39 -0.32 -0.11 -0.11 -0.22
Q3 0.04 0.13 -0.10 -0.21 -0.11 0.06 -0.02 -0.11
Parkinson’s disease # 17 23 29 25 17 24 30 25
Median (Q2) 0.41 0.36 0.59 1.23 0.18 0.03 0.24 0.14
Q3 1.69 0.99 1.82 1.56 1.32 0.50 0.81 0.63
Alzheimer’s c.a # 17 24 31 25 17 24 31 25
Q1 0.74 -0.16 -0.36 0.39 0.85 0.19 0.00 1.01
Median (Q2) 1.74 1.21 1.38 1.75 1.56 1.46 1.01 1.87
Q3 3.45 1.94 2.55 3.46 3.54 2.39 2.68 4.70
Multiple sclerosis # 27 30 28 28 27 32 30 29
Q1 -0.20 -0.18 -0.28 -0.39 -0.30 -0.37 -0.14 -0.33
Median (Q2) -0.05 0.03 -0.06 -0.12 -0.02 -0.10 -0.01 0.06
Epilepsy # 27 32 30 29 27 30 29 29
Q1 -0.38 -0.61 -0.12 -0.44 -0.41 -0.43 -0.13 -0.38
Median (Q2) 0.06 -0.12 0.17 -0.07 -0.13 -0.06 0.12 -0.06
Q3 0.31 0.27 0.32 0.22 0.18 0.14 0.24 0.15
Note: Q1, Q2 and Q3 represent the first quartile, second quartile (or median) and third quartile of the age-standardized mortality rates of all European countries
with available data at that point in time. # denotes number of countries in the analysis.
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psychoactive substance use and Parkinson’s disease has
also risen in several countries. Mortality from dementiashas risen particularly strongly in Finland, Iceland, Malta,
Netherlands, Spain, Sweden and the United Kingdom, and
is positively associated with self-expression values, average
a. All dementias
b. Psychoactive substance use
c. Parkinson’s disease
Figure 3 The rise of age-standardized mortality from (a) all
dementias, (b) psychoactive substance use, and (c) Parkinson’s
disease, countries in upper quartile of mortality change, men.
Note: Countries in upper quartile of change in age-standardized
mortality between 1991 and 2009. Age-standardized mortality rates all
ages (in deaths per 100,000 person-years).
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only the first has an independent effect.Limitations
This is the most comprehensive study ever of trends
in mortality from mental and neurological diseases in
Europe, but such wide coverage comes at the expense
of relying on official mortality statistics by cause of
death. There is no doubt that the conditions studied
in this paper increase the risks of dying. For example,
the relative risk of dying among dementia patients, as
compared to people without dementia of the same
age, is between 2 and 3 [39], and that of patients
with Parkinson’s disease is between 1.5 and 2.5 [40].
However, their exact role in causing death in individual
patients is often less clear, and leaves room for considerable
differences in cause-of-death classification.
This has most extensively been studied for dementias.
The immediate cause of death of patients with dementia
is often pneumonia or cardiovascular disease, and
dementia is not always mentioned on death certificates,
particularly if death occurs in general hospitals instead
of in nursing homes or psychiatric hospitals [41]. Even if
dementia is mentioned on the death certificate, it is not
always selected as the underlying cause of death,
although this has improved with the separate listing of
various forms of dementia in ICD-9 and ICD-10 [9] and
with changes in coding rules which have more explicitly
recognized the possible role of dementia as an underlying
cause of death [8,26,42]. Underrecording may also apply to
Parkinson’s disease [20,43] or to psychoactive sub-
stance use [17]. This has led some researchers to
combine dementia coded as an underlying cause with
dementia coded as a contributory cause [8,44–46].
This approach certainly removes some of the underre-
cording of dementia and has been shown to correctly
identify a high proportion of dementia cases [47,48].
It would therefore be interesting to compare our re-
sults with those from an analysis based on all men-
tions of dementia on death certificates, but this was
not feasible in the study reported in this paper as the
WHO Mortality Data Base only contains information
on underlying causes of death. The implication is that
our study is likely to underestimate the role of
dementia as a cause of death, and because this under-
estimation is likely to also differ between countries,
a. Men
b. Women
Figure 4 Age-standardized rates of mortality from all dementias in Europe, 2009, persons aged 65 and over. a. Men. b. Women.
Note: No deaths from dementia among men reported from Portugal and TFYR Macedonia.
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the between-country variations seen in our study.
Studies of time-trends in the incidence of dementia
and other mental and neurological conditions are scarce.
The limited evidence-base, however, does not suggest a
rise in the incidence in these conditions. Community
studies in the United States have not detected clear timetrends in the incidence of dementia [27,49], while a
study from the same country based on medical records
reported an increase [50]. Community studies from the
Netherlands and England even found declines in the
incidence or prevalence of dementia [51,52]. Incidence or
prevalence of Parkinson’s disease have probably not been
rising either [53]. With regard to psychoactive substance
a. Men
b. Women
Figure 5 Age-specific mortality rates from all dementias, countries in upper quartile of mortality, 2009. a. Men. b. Women.
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variability in trends in alcohol consumption, with rising
trends in, e.g., Finland and the United Kingdom (cf.
Figure 3b), and a lack of comparative data on trends
in other health outcomes than mortality [54].
It is unlikely, therefore, that the increase in mortality
from dementia as found in many European countriesrepresents an increase in incidence of the disease. As
it is also unlikely that survival of patients with
dementia has declined substantially, this leaves im-
proved recognition, diagnosis, certification and/or
coding as the most likely explanation for the increase
in mortality from dementia. The same may apply to
Parkinson’s disease.
Table 2 Association between mortality from all dementias and potential determinants: results of regression analysis
Univariate Bivariate
Beta Beta Beta Beta Beta Beta Beta
S.E. S.E. S.E. S.E. S.E. S.E. S.E.
Men Self-expression values 54.77 50.34 48.73 54.57
14.59**** 18.53** 28.72 20.15**
Average income 4.35 0.04
1.95** 2.36
Health care expenditure 27.55 5.43
12.20** 13.60
Life expectancy, men 13.84 2.01
4.38*** 8.15
Women Self-expression values 65.19 64.31 52.15 65.16
14.54**** 18.24*** 23.89** 19.97***
Average income 5.10 0.00
2.03** 2.33
Health care expenditure 27.74 1.07
12.66*** 12.98
Life expectancy, women 27.34 7.84
7.45*** 11.33
Notes: The table shows the regression coefficient (Beta) as well as its standard error (S.E.). In a forward selection procedure, age-standardized mortality from All
dementias (aged 65 and over) was regressed on four possible determinants separately (“univariate”), and on self-expression vs. survival values and each of the
other possible determinants separately (“bivariate”). Average income: Beta multiplied by 1000 (thus indicating effect of GDP, in 1000I$ per capita, on mortality).
*p < .10 **p < .05 ***p < .01 ****p < .01.
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from dementias and from “senility”, a now obsolete
category in the International Classification of Diseases
that may have contained many cases of unrecognized
dementia [55], shows that national levels of mortality
from both conditions were indeed negatively correlated
throughout the study period, but not very strongly so
(web Additional file 4: Table S4). In some countries,
such as Spain and Estonia, declining mortality from
senility coincided with increasing mortality from
dementias, but in others, such as Finland and Bulgaria,
the trends do not suggest a transfer of deaths from one to
the other category (web Additional file 5: Figure S1).
Interpretation
Changes in recognition, diagnosis, certification and/or
coding of dementia also reflect changes in physicians’
and statisticians’ attitudes, in this case towards the
possible role of dementia as a cause of death. Our
findings on the association between cultural values
and mortality rates from dementia should probably be
interpreted in this sense.
We hypothesized that health care professionals in
populations that adhere more closely to values of
self-expression and quality of life instead of mere survival,
are more willing to recognize mental and neurological
conditions as a possible cause of death, and/or torefrain from life-saving treatments in dementia patients
with low quality of life. Our results can be seen to support
this hypothesis: mortality from dementias is indeed higher
in countries scoring higher on the self-expression versus
survival values scale. This can probably be explained from
the fact that a greater emphasis on quality of life as the
main purpose of health care interventions may first lead
to a greater awareness of dementia and other non-directly
fatal diseases for elderly patients’ well-being, and then to a
greater recognition of these conditions as the ultimate
causes of their patients’ deaths. We have recently demon-
strated that self-expression values are strong predictors
of between-country variations in a wide range of
health-related behaviours [30].
One could perhaps even raise the issue of whether
rapidly rising rates of mortality from dementia indicate a
greater willingness of health care professionals to refrain
from life-saving treatment in the face of a debilitating
illness. As long as its complications are adequately
treated, dementia will in itself not lead to death, so when
a death is certified as caused by dementia, the physician
has probably decided that further treatment was useless
[56]. Some of the countries with the highest mortality
rates from dementia (e.g., Sweden, Netherlands, Denmark,
Belgium) are among the countries with the highest public
acceptance rates of euthanasia, and acceptance rates of
euthanasia are also closely associated with “modern” value
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between the two phenomena is far from perfect, as
illustrated by Malta which combines very high mortality
from dementia with very low public acceptance of euthan-
asia [57]. Euthanasia practice is also not necessarily more
liberal in the North of Europe than in other parts of the
subcontinent [58]. It is therefore more likely that rising
rates of dementia more simply reflect the greater recogni-
tion of the debilitating nature of this disease that comes
with modern shifts in value orientations.
Conclusions
Although trends in mortality from dementias have
probably been affected by changes in cause-of-death
classification, the high level of mortality from these
conditions in a number of vanguard countries suggests that
it is now among the most frequent causes of death in
high-income countries. Recognition of dementias as a
cause of death, and/or refraining from life-saving
treatment for patients with dementia, appear to be
strongly dependent on cultural values.
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